EGFR and chordoma: Supported by these data, a European multicentre clinical trial involving a second-generation EGFR inhibitor (afatinib or Giotrif®, Boehringer Ingelheim, Ingelheim, Germany) is currently enrolling patients with advanced and metastasising chordoma (ClinicalTrials.gov Identifier: NCT03083678) [11].